BiolineRX raises $24m in Nasdaq offering
Judge Ariella Gilzer-Kats: We were shown a dismal picture, which is inappropriate for a company in a civilized country.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), long considered the flagship of Israeli industry, has thousands of employees and makes a very big contribution to the economy. It donates to social organizations, and has won awards for its social contribution, and has been named an outstanding employer for its treatment employees called up for reserve military duty.
But bad things are apparently happening beneath the surface at Teva. A recent ruling by the Tel Aviv District Labor Court reveals the bitter story of the late Tali Oren-Blazer, an assistant of former Teva president and CEO Israel Makov, who was fired after she was diagnosed with a malignant brain tumor.
Judge Ariella Gilzer-Kats ruled that Teva fired Oren-Blazer, after the tumor was diagnosed, because of her illness, and ordered the company to pay her heirs NIS 2 million, plus NIS 170,000 in court costs. In the ruling, Judge Gilzer-Kats sharply criticized Teva's conduct, saying, "We were shown a dismal picture, which is inappropriate for a company in a civilized country, especially for a public company."
In its defense, Teva said that it acted properly toward Oren-Blazer, and acted beyond the strict requirement of the law, at both the personal and financial levels. The company said that complaints had been made against Oren-Blazer in her job as assistant to the CEO.
Teva said in response, "Teva president and CEO Jeremy Levin has instructed the company's lawyers not to file an appeal against the ruling."
Teva's current management is not pleased by the company's conduct in the firing of Oren-Blazer. In a letter to employees today, Levin responded to today's court ruling against the company, saying, "I regret our conduct in this affair over the years, and the lack of sensitivity and common sense in the handling of the humane case of Tali, RIP." He added that he had instructed the company to draw lessons from the case.
"I wish to emphasize to you in the strongest way that a situation of this kind should never have begun, and that it contravenes the values of the company," added Levin in the letter, a copy of which "Globes" has obtained.
Published by Globes [online], Israel business news - www.globes-online.com - on May 6, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.